公开(公告)号：US09273106B2

公开(公告)日：2016-03-01

申请号：US14134482

申请日：2013-12-19

Applicant: Amgen Inc.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/50 ,  C12N15/12 ,  C12N15/63 ,  C07K16/18 ,  A61K38/00

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.

Abstract translation: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。

公开(公告)号：US11840558B2

公开(公告)日：2023-12-12

申请号：US17357444

申请日：2021-06-24

Applicant: AMGEN INC.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/05 ,  A61K39/00 ,  A61K38/00 ,  C07K16/18

CPC classification number: C07K14/05 ,  A61K38/1825 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

公开(公告)号：US20210317176A1

公开(公告)日：2021-10-14

申请号：US17357444

申请日：2021-06-24

Applicant: AMGEN INC.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: C07K14/50 ,  A61K38/18

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

公开(公告)号：US20180000898A1

公开(公告)日：2018-01-04

申请号：US15671923

申请日：2017-08-08

Applicant: Amgen Inc.

Inventor： Murielle Marie Ellison ,  Shanaka Stanislaus ,  Jing Xu

IPC: A61K38/18

CPC classification number: A61K38/1825

Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease

公开(公告)号：US20140323396A1

公开(公告)日：2014-10-30

申请号：US14167662

申请日：2014-01-29

Applicant: AMGEN INC.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: C07K14/50

CPC classification number: C07K14/50 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。